About US
Contact us
-
Celgene fights for sanction on patent challenger BassCelgene ($CELG) is hedge fund managerKyle Bass' latest patent target, it says--but the biotech isn't taking the news lying down. The New Jersey company has asked the U.S. Patent and Trademark Office2015/7/31
-
Glaxo posts 'unremarkable' results in first quarter after Novartis swapOn Wednesday, GlaxoSmithKline ($GSK) announced results for its first full quarter after closing its blockbuster asset swap with Novartis ($NVS). And so far, things look "unremarkable." That's the way2015/7/30
-
Analysts: Mylan won't land Perrigo, even with Teva out of the wayTeva's ($TEVA) $40.5 billion deal to buy Allergan's ($AGN) generics business ended its pursuit of Mylan ($MYL) and left its rival the chance to snap up its own hostile target, Perrigo ($PRGO). But the2015/7/30
-
Drug Administration Law of the People's Republic of China reissued after the amendment adopted at the 14th Meeting of the Standing Committee of the Twelfth National People's CongressThe Decision of the Standing Committee of the National People's Congress on Amending the Drug Administration Law of the People's Republic of China was adopted at the 14th Meeting of the Standing Commi2015/7/29
-
Sanofi hands Regeneron $1.8B for new immuno-oncology pactAfter winning approval for their PCSK9 drug Praluent last week, longtime partners Sanofi ($SNY) and Regeneron ($REGN) are back at it with a new collaboration. The French pharma giant will pay at least2015/7/29
-
With new cash on its way, it's back to buying for deal-happy Allergan, CEO saysOn Monday, Allergan ($AGN) agreed to sell off a $40.5 billion piece of its business, inking a pact to exit the generics space with a sale to Teva Pharmaceutical Industries ($TEVA). But CEOBrent Saunde2015/7/29
-
About that brand/generics hybrid thing? Make that brands only, Allergan says with Teva dealIt's been less than 8 months since the company formerly known asActavisagreed to swallow Allergan ($AGN), taking a $66 billion plunge into branded sales and pledging to run its branded and generics bu2015/7/28
-
Aegerion dumps CEO who got it into FDA trouble for talking too freelyAegerion Pharmaceuticals ($AEGR) CEO Marc Beer may be a fast talker but he has been a bit of a slow walker when it comes to giving up his position as CEO. The executive, who got the company into troub2015/7/28
-
Cancer docs try to rally public behind plan to fight drug pricesCancer doctors at the famed Mayo Clinic have been up in arms about escalating prices ofcancer drugs. Now they have recruited a bunch of colleagues and are trying to rile up the public in hopes of star2015/7/27
-
UnitedHealth uses newfound scale to negotiate pay-for-performance dealsNewly bulked-up UnitedHealth ($UNH) now boasts the U.S.' third largest pharmacy benefits business--and it's using its scale to push for refunds when meds don't live up to their billing, it says. The2015/7/27